Intraoperative radiotherapy: An alternative to whole‐breast external beam radiotherapy in the management of highly selective breast cancer: A SEER database analysis
Cancer Medicine · 2024
DOI: 10.1002/cam4.7458 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Dexun Sun und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Breast Neoplasms, SEER Program, Mastectomy, Segmental. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Guangzhou Basic Research Programme Municipal School (Hospital) Joint Funded Foundation and Application Basic Research Project.
Abstract (Originalsprache)
Objective
This study aimed to verify if intraoperative radiotherapy (IORT) can achieve the same survival outcome as whole‐breast external beam radiotherapy (EBRT) in early breast cancer after breast‐conserving surgery (BCS), and to explore the suitable candidates that can safely receive IORT after BCS.
Methods
Eligible post‐BCS patients who received IORT or EBRT were included in the Surveillance, Epidemiology and End Results (SEER) database from 2010 to 2018. Risk factors that affected 5‐year overall survival (OS) or breast cancer specific survival (BCSS) were identified by Cox proportional hazards regression analysis. Clinical characteristics, OS, and BCSS were comparatively analyzed between the two treatment modalities.
Results
The survival analysis after propensity score matching confirmed that patients who received IORT ( n = 2200) had a better 5‐year OS than those who received EBRT ( n = 2200) ( p = 0.015). However, the two groups did not differ significantly in 5‐year BCSS ( p = 0.381). This feature persisted even after multivariate analyses that took into account numerous clinical characteristics. Although there was no significant difference in BCSS between different subgroups of patients treated with IORT or EBRT, patients over 55 years of age, with T1, N0, non‐triple negative breast cancers, hormone receptor‐positive, and histologic grade II showed a better OS after receiving IORT.
Conclusion
In low‐risk, early‐stage breast cancer, IORT was not inferior to EBRT considering 5‐year BCSS and OS. Considering the equivalent clinical outcome but less radiotoxicity, IORT might be a reasonable alternative to EBRT in highly selective patients undergoing BCS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Breast Surgery, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
- Department of Medical Statistics, School of Public Health, Sun Yat-sen University, Guangzhou, Guangdong, China.
ORCID-Profile: Guanhua Lu, Xinxin Chen
Förderung
- Guangzhou Basic Research Programme Municipal School (Hospital) Joint Funded Foundation and Application Basic Research Project
Zitieren
APA
Sun, D., Lu, G., Liang, F., Zhang, W., Zeng, T., Ling, Y., Peng, H., Xia, T., Hu, M., & Chen, X. (2024). Intraoperative radiotherapy: An alternative to whole‐breast external beam radiotherapy in the management of highly selective breast cancer: A SEER database analysis. Cancer Medicine. https://doi.org/10.1002/cam4.7458
Vancouver
Sun D, Lu G, Liang F, Zhang W, Zeng T, Ling Y, et al. Intraoperative radiotherapy: An alternative to whole‐breast external beam radiotherapy in the management of highly selective breast cancer: A SEER database analysis. Cancer Medicine. 2024. doi:10.1002/cam4.7458
BibTeX
@article{Sun2024,
author = {Sun, Dexun and Lu, Guanhua and Liang, Fenmei and Zhang, Wangjian and Zeng, Tao and Ling, Yun and Peng, Haojie and Xia, Ting and Hu, Meilin and Chen, Xinxin},
title = {Intraoperative radiotherapy: An alternative to whole‐breast external beam radiotherapy in the management of highly selective breast cancer: A SEER database analysis},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.7458}
}
EUVIMED